Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
142 hedge funds and large institutions have $2B invested in Apellis Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 72 increasing their positions, 37 reducing their positions, and 15 closing their positions.
95% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 37
30% more capital invested
Capital invested by funds: $1.53B → $2B (+$464M)
22% more call options, than puts
Call options by funds: $8.24M | Put options by funds: $6.76M
5.17% more ownership
Funds ownership: 75.86% → 81.03% (+5.2%)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less funds holding
Funds holding: 143 → 142 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$57.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.5M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$26.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$20.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$56.8M |
| 2 |
EP
Eversept Partners
New York
|
-$15.4M |
| 3 |
Millennium Management
New York
|
-$9.07M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$9M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.42M |
APLS Hedge Fund Activity: Q2 2020 in Review
142 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2020, worth a combined $2B — up 30% from $1.53B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new APLS positions and 15 closed out — a net gain of 1 holder — while 72 added to existing stakes and 37 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $57.1M. The largest seller was Victory Capital Management, cutting an estimated $56.8M.
- 142 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2020, down from 143 in Q1 2020.
- Funds reported $2B of Apellis Pharmaceuticals stock for Q2 2020, up 30% quarter-over-quarter.
- 16 funds opened new Apellis Pharmaceuticals positions in Q2 2020 and 15 closed out, a net change of +1 holder.
- The largest Apellis Pharmaceuticals buyer in Q2 2020 was T. Rowe Price Associates, an estimated $57.1M added.
- The largest Apellis Pharmaceuticals seller in Q2 2020 was Victory Capital Management, an estimated $56.8M sold.
Based on aggregated 13F filings for Q2 2020.